Yahoo Finance's Julia La Roche sits down with executive chairman and former CEO of Starbucks Howard Schultz
|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||45.63 - 47.11|
|52 Week Range||41.00 - 58.79|
|PE Ratio (TTM)||28.32|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||72.00|
LYNBROOK, N.Y., Sept. 20, 2017 /PRNewswire/ -- BioSpecifics Technologies Corp. (BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming 2017 Cantor Fitzgerald Global Healthcare Conference at 2:15 p.m. ET on Wednesday, September 27, 2017 in New York, NY. A live audio webcast of each presentation can also be accessed under the "Events and Presentation" tab in the Investors section of the Company's website at www.biospecifics.com or at http://wsw.com/webcast/cantor6/bstc. BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for thirteen clinical indications to date.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Biospecifics Technologies Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)
BioSpecifics Technologies Corp (NASDAQ:BSTC) trades with a trailing P/E of 28.7x, which is lower than the industry average of 37.2x. While BSTC might seem like an attractive stock to buy,Read More...